Alnylam Pharmaceuticals, BioMarin Pharmaceutical Inc., And Cytonet Set To Speak On Conducting Effective Orphan Drug Research


Barbara Wuebbels, R.N., M.S., Oved Amitay, and Rod Monroy, Ph.D. set to speak at the Premier marcus evans Life Cycle of Orphan Drug Development & Commercialization Conference

Chicago, IL (I-Newswire) November 15, 2012 - marcus evans, a world leading provider of strategic conferences is pleased to introduce the Life Cycle of Orphan Drug Development & Commercialization Conference, January 16-18, 2013 in Boston, Mass.

The orphan drug and rare disease industry is one of the hottest topics in modern day medicine. â€?“A unique set of patients with rare diseases and severe unmet medical needs exists; it is essential to have people and companies dedicated to develop therapeutic agents to improve the quality of life for these patients,â€?? said Rod Monroy, Ph.D., Senior Director, North American Clinical Operations at Cytonet. With blockbuster drugs coming off patent, there is a great need for pharmaceutical companies to diversify their portfolios by exploring niche markets. The increasing presence of high-profile manufacturers in the orphan drug industry provides these companies with this opportunity.

Orphan drug development has several advantages including faster clinical trials, better odds for approval with an 82% success rate, attractive profitability, given the smaller patient populations, and ongoing revenue growth.

While the orphan drug market offers an attractive future for the pharmaceutical industry, it is not without challenges, which include clinical trial end points and lack of biomarkers and difficulty identifying patients. â€?“Finding key opinion leaders and funding the clinical trial are two of the major challenges in orphan drug development,â€?? said Barbara Wuebbels, Associate Director, Patient Advocacy & Investigator Relations at BioMarin Pharmaceutical Inc.

Growing regulatory issues and demands, a changing reimbursement environment, and outdated distribution models add uncertainty and increase the financial risks. â€?“As we continue to drive scientific innovation to the benefit of patients we need to work with other stakeholders on evolving the commercial paradigms to ensure sustainable long-term success,â€?? said Oved Amitay, Vice President and Head of Commercial at Alnylam Pharmaceuticals.

The Life Cycle of Orphan Drug Development & Commercialization Conference will focus on the current landscape of rare disease and orphan drug development, different forms of structural based drug designs, and specifically designed clinical trials. Through these clinical trials, and by having connected to the right patients to participate, will increase productivity and expedite orphan drug approval and commercialization of the final product.

For more information regarding this conference and to register, please visit http://www.marcusevansch.com/LCOD2012_PR or contact Robin Yegelwel, Marketing & PR Coordinator, at (312) 540-3000 ext. 6483 or robiny@marcusevansch.com

About marcus evans

marcus evans conferences annually produce over 2,000 high quality events designed to provide key strategic business information, best practice and networking opportunities for senior industry decision-makers. Our global reach is utilized to attract over 30,000 speakers annually; ensuring niche focused subject matter presented directly by practitioners and a diversity of information to assist our clients in adopting best practice in all business disciplines.






About marcus evans

marcus evans conferences annually produce over 2,000 high quality events designed to provide key str   More..ategic business information, best practice and networking opportunities for senior industry decision-makers. Our global reach is utilized to attract over 30,000 speakers annually; ensuring niche focused subject matter presented directly by practitioners and a diversity of information to assist our clients in adopting best practice in all business disciplines.Less..

Contact Information

marcus evans
Robin Yegelwel

Published in:

Events / Trade Shows

Published On:

November 15, 2012

Print Release:

Print Release

If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.


Related Releases

28th Annual Celebration In Key West Florida Is All About "Today's The Day!"
This July 10th-13th is the 28th annual Mel Fisher Days, celebrating one of Key West's most colorful residents and the World's greatest treasure hunter.

Video Game Convention Hosted by PwnEm Slated for August 2nd in New Jersey
Started in 2012, the social video game gathering brings together gamers of various skill levels and ages for a day of fun entertainment and exciting prizes.

Creating the Best Wedding Day Memories with Wedding Cakes From WeddingCake.org
While cupcakes have become the latest wedding trend to hit the market, a recent survey results have shown that more than 68% of couples still opt for a traditional tiered wedding cake.

Irene Behnan, Ph.D, Will Present At The American Association of Anger Management Providers
The title of her presenation "The role of Emotional Intelligence in the Life of Couples"

Edward Daube, Ph.D, Will Present The American Asso
The title of his presentation is "From Anger Management to Anger Mastery: Taking Emotional Intelligence to the Next Level"